Fact Sheet Array BioPharma

Fact Sheet
Array BioPharma
In the News
About Array BioPharma
2/1/16
Array initiates Immuno‐Oncology research collaboration with Dana Farber Cancer Institute
Array BioPharma Inc. is a biopharmaceutical 12/16/15
Array announces Phase 3 binimetinib trial meets primary endpoint for NRAS‐mutant melanoma
11/16/15
Array and Pierre Fabre announce collaboration for Binimetinib and Encorafenib
Analysts
Mara Goldstein
Cantor Fitzgerald
NASDAQ
ARRY
company focused on the discovery, Stock Price (2/9/16)
$2.50
development and commercialization of Market Capitalization
$357.5 million
52 Week Range
$2.50‐8.59
Shares Outstanding
143 million
cancer drugs. These programs include R&D Staff
100
binimetinib , encorafenib and selumetinib Cash (12/31/15)
$185.4 million
(partnered with AstraZeneca). Headquarters
Boulder, CO
targeted small molecule drugs to treat patients afflicted with cancer. Six phase 3 studies are currently advancing related to three Path to Commercialization
Upcoming Catalysts for Array
Eun Yang
Jeffries & Co.
Anupam Rama
JP Morgan
Michael Schmidt
Leerink Swann
Ted Tenthoff Piper Jaffray
Stephen Willey Stifel Nicolaus
Matthew Andrews
Wells Fargo
Major Shareholders
Redmile Group, LLC Fidelity Management & Research OrbiMed Advisors, LLC Deerfield Management Co., L.P.
Biotechnology Value Fund, Inc.
BlackRock Inst’l Trust Co., N.A.
T. Rowe Price Associates, Inc.
Vanguard Group, Inc.
State Street Global Advisors (US)
Baker Bros .Advisors, LP
Pinnacle Associates, Ltd.
MILO: MEK Inhibitor in Low Grade Serous Ovarian Cancer; NEMO: NRAS melanoma and MEK inhibitor; COLUMBUS: Combination of
LGX818 used with MEK162 in BRAF mutant unresectable skin cancer; ASTRA: Pivotal trial in differentiated thyroid cancer; SELECT-1:
selumetinib + docetaxel in patients with KRAS NCSLC
Strategy
We are building a fully‐integrated, commercial‐stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer. We intend to accomplish this through the following strategies:
•
Invent targeted small molecule drugs that are either first‐in‐class or second generation drugs that have little or no competition, or demonstrate a competitive advantage over drugs currently on the market or in clinical development.
•
Develop and commercialize our drugs to maximize their overall value. As our first drug nears approval, we plan to build a therapeutically‐focused sales force to commercialize or co‐promote drugs we wholly own, or for which we retain development rights in major geographic areas.
•
Implement a partnering strategy in which we out‐license drugs outside our therapeutic or geographic focus and partner select early‐stage programs for continued research and development to receive research funding plus significant milestone payments and royalties.
Array’s Top Priority
Binimetinib & Encorafenib Development & Commercialization
Board of Directors
Executive Team
Ron Squarer
CEO
Ron Squarer
CEO
Charles M. Baum, M.D.,
Ph.D.
President & CEO, Mirati
Therapeutics
Dave Horin
Interim CFO
Gwen A. Fyfe, M.D.
Independent Consultant
Genentech*
Kimberly Pope
VP Human Resources
Kyle A. Lefkoff
Chairman
Boulder Ventures
John A. Orwin
CEO
Relypsa
John R. Moore
VP & General Counsel
Selected
Collaborators
AstraZeneca
Biogen Idec
Celgene
Genentech/Roche
Oncothyreon
Pierre Fabre
Andrew Robbins
COO
Nick Saccomano, Ph.D.
CSO
Victor Sandor, M.D.
CMO
Gil J. Van Lunsen
KPMG*
*prior employers
3200 Walnut Street
Boulder, Colorado 80301
Phone: 303.381.6600
Fax: 303.381.1390
www.arraybiopharma.com
[email protected]
Safe Harbor Statement:
This document contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on Form 10‐K for the fiscal year ended June
30, 2015, and in other reports filed by Array with the Securities and Exchange Commission. In addition, we may make forward‐looking statements in our press releases or in other oral or written communications with the public. These statements do not relate to historical
matters and reflect our current expectations concerning future events. Therefore our actual results could differ materially from those anticipated in these forward‐looking statements as a result of many factors. These factors include, but are not limited to, our ability to
continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in‐license drug
candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out‐license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical
development and commercialization of our out‐licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, our ability to attract and retain experienced scientists and management, and the risk factors set forth
below under the caption “Risk Factors.” We are providing this information as of the date of this report. We undertake no duty to update any forward‐looking statements to reflect the occurrence of events or circumstances after the date of such statements or of
unanticipated events that alter any assumptions underlying such statements.